Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 128

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 128
---
 the first six months of 2024, and for the years ended December
31, 2023 and 2022, finance expenses were comprised primarily of interest payable on lease liabilities and other loans.

Taxation

Taxation
represents tax credits receivable by Group companies in respect of qualifying research and development costs incurred.

Results of Operations

Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023

The following table summarizes our consolidated
results of operations for the six month periods ended June 30, 2024 and 2023:

|                                                              |     |  Six Months Ended June 30, |        |   |     |      |        |   |
|                                                              |     |                       2024 |        |   |     | 2023 |        |   |
|                                                              |     | -£ in thousands; unaudited |        |   |     |      |        |   |
| Revenue                                                      |     |                            |     -- |   |     |      |    298 |   |
| Other income                                                 |     |                            |     -- |   |     |      |     -- |   |
| Research and development costs                               |     |                            | (2,189 | ) |     |      | (2,251 | ) |
| Administrative costs                                         |     |                            | (2,034 | ) |     |      | (2,291 | ) |
| Loss from operations                                         |     |                            | (4,223 | ) |     |      | (4,244 | ) |
| Finance income                                               |     |                            |    839 |   |     |      |    410 |   |
| Finance expense                                              |     |                            |    (49 | ) |     |      |    (22 | ) |
| Loss before tax                                              |     |                            | (3,433 | ) |     |      | (3,856 | ) |
| Taxation                                                     |     |                            |    125 |   |     |      |    288 |   |
| Loss for the period attributable to the owners of the parent |     |                            | (3,308 | ) |     |      | (3,568 | ) |

Revenue. Total
revenue for the six months to June 30, 2024 was £Nil compared to £0.30 million in the first six months of 2023. The research
and development collaboration with Jans